Assessment of Breast Cancer Risk Based on Mammary Gland Volume Measured with CT by Kuchiki, Megumi et al.
Breast Cancer: Basic and Clinical Research 2010:4 57–64
doi: 10.4137/BCBCR.S5248
This article is available from http://www.la-press.com.
© the author(s), publisher and licensee Libertas Academica Ltd.
This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Open Access
Full open access to this and 
thousands of other papers at 
http://www.la-press.com.
Assessment of Breast cancer Risk Based on Mammary  
Gland Volume Measured with ct
Megumi Kuchiki1,2, Takaaki Hosoya2 and Akira Fukao1
1Department of Public Health and 2Department of Diagnostic Radiology, Faculty of Medicine, Yamagata University,  
2-2-2 Iida-nishi, Yamagata 990-9585, Japan. Corresponding author email: mkuchiki@med.id.yamagata-u.ac.jp
Abstract: We investigated the relationship between mammary gland volume (MGV) of the breast as measured with three-dimensional 
chest computed tomography (CT) and breast cancer risk. Univariate analysis was used to assess the relationship between MGV and 
known risk factors in 427 healthy women. A case control study (97 cases and 194 controls) was conducted to assess breast cancer risk. 
MGV was significantly smaller for postmenopausal women than for premenopausal women, and was significantly larger for women 
with a family history of breast cancer than for women without. MGV, body mass index (BMI), and rate of family history of breast cancer 
were significantly higher among breast cancer patients than among healthy women, and number of deliveries was significantly lower 
among breast cancer patients. In postmenopausal women, age at menarche was significantly younger for breast cancer patients. MGV 
correlated well with breast cancer risk factors. The highest odds ratio was 4.9 for premenopausal women with the largest MGV. Regard-
less of menopausal status, the greater the MGV, the higher the odds ratio. Our results constitute the first reliable data on the relationship 
between MGV and breast cancer obtained through exact volume analysis.
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The  relative  proportion  of  radio-opaque  stroma, 
  including epithelial tissues, to the entire breast as deter-
mined by mammogram is known as   mammographic 
density  (MD)  or  mammographic  breast  density. 
Many studies have found that MD correlates to breast 
cancer risk, namely, the greater the MD, the higher 
the risk.1–4 A significant question that remains unan-
swered is whether or not MD is a good indicator of 
the stromal volume of the breast. MD is not an abso-
lute volume but a relative parameter that is affected 
by changes in fat proportion due to changes in body 
weight.5 In addition, the reproducibility of MD find-
ings  is  problematic.  Because  MD  does  not  repre-
sent the natural state of the breast, MD values can 
vary  under  different  scanning  conditions.6  Several 
studies investigating breast cancer risk have instead 
used the area of mammographic dense tissue as the 
  measurement of the absolute volume,7 though these 
two measurements are not actually equivalent.
Since breast cancer arises in the mammary glands, 
its onset should theoretically depend on the mammary 
gland volume (MGV) of the breast.8 In this study, we 
aimed to investigate the relationship between MGV of 
the breast as measured with three-dimensional chest 
computed tomography (CT) and breast cancer risk.
Materials and Methods
Subjects
The initial pool from which subjects were drawn con-
sisted of 153 patients who underwent surgery for breast 
cancer at our university hospital between January 2002 
and December 2006. In our hospital, all breast cancer 
patients routinely undergo preoperative   abdomen–chest 
CT to evaluate metastasis or to screen for other disease. 
Of these patients, 20 who died or whose current address 
was unknown and 5 who did not have preoperative CT 
and mammography data collected at our hospital were 
excluded. A written explanation of the present study 
was provided to the remaining 128 patients by mail or 
during outpatient visits to ask for their participation. 
Twenty-six patients did not reply and thus, a total of 
102 women participated by filling out the above-men-
tioned self-administered questionnaire (66.7% of the 
total   subject population).
Control subjects were members of a public school 
teaching  union  in  northeastern  Japan.  Their  cancer 
screening  included  complete  physical  examinations 
that  incorporated  breast  cancer  screening  including 
  mammography  and  lung  cancer  screening  based  on 
chest CT. Eight hundred and ninety-nine women out 
of 970 women who had undergone   cancer screening 
between  September  2006  and  February  2007  were 
  control subjects who had undergone both   mammography 
and chest CT. We recruited potential study participants 
from among these women by distributing a written 
explanation of the present study. A total of 528 women 
participated by filling out a self-administered question-
naire. Of the questionnaire respondents, we excluded 
54 women whose medical test results suggested breast 
cancer. We also excluded women with a history of 
breast cancer and women who had undergone artificial 
menopause due to premenopausal uterine or ovarian 
disease; this removed another 47 women from the par-
ticipant pool. Hence, 427 women participated (47.5% 
of those who underwent the complete physical exami-
nation during the study period).
For  the  case  control  study,  two  age-matched 
healthy control subjects were randomly selected per 
patient  (age  difference:  ±2  years).  Subsequently, 
a total of 97 breast cancer patients and 194 healthy 
women were also enrolled.
The present study protocol was approved by the 
Local Research Ethics Committee.
Methods
Measurements and analysis  
of data from control subjects
CT was performed on all subjects by a single radi-
ologist  who  is  skilled  at  diagnostic  imaging  and 
computer-assisted  measurement.  MGV,  including 
fibrous and vascular components of the breast, was 
measured using chest CT data obtained during lung 
cancer screening. CT was performed using an Aquil-
lion16 system (Toshiba Medical Systems Corpora-
tion, Tokyo, Japan) with a tube voltage of 120 kV 
and a current of 30 mA. The area from the supra-
clavicular fossa to below the diaphragm was imaged 
through 16-row helical scanning. The pixel size of the 
resulting images was 0.78 mm × 0.78 mm × 0.5 mm; 
images were reconstructed with a slice thickness of 
5 mm and a slice interval of 5 mm without any gaps. 
Images were displayed with a field of view (FOV) 
of 40 cm and a matrix size of 512 × 512. All images 
were saved as Digital Imaging and Communications 
in Medicine (DICOM) files. Images were displayed 
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Image J software.9
The maximum CT value of a region of interest 
(ROI) with a diameter of 6 to 20 mm set at the axillary 
fat in each patient was used as a reference value. The 
breast was manually identified excluding the skin, and 
the mammary gland was defined as all areas with CT 
values higher than the reference CT value (Fig. 1). 
This process was repeated for the entire breast, and 
the  total  number  of  pixels  identified  as  mammary 
gland  tissue  was  multiplied  by  the  slice  thickness 
(5 mm) to calculate MGV. Under these scanning con-
ditions, each pixel was equivalent to 0.003 cm3.
The  CT  scans  of  30  of  the  427  subjects  were 
  randomly selected. The concordance rate of left and 
right MGV was investigated to confirm the reliability 
of measuring MGV through CT.10
Body  mass  index  (BMI)  was  calculated  based 
on  height  and  body  weight  measured  during 
  examinations.  The  self-administered  questionnaire 
included items on age at menarche, parity (number 
of childbirths), age at first live delivery, duration of 
infant breastfeeding, age at menopause, and family 
history of breast cancer.
MGV was assessed in relation to family   history 
and menopausal status. Patients were asked to report 
family history of breast cancer within two genera-
tions  (grandmother,  mother,  sister,  daughter,  and 
granddaughter).  Relationships  between  MGV  and 
other breast cancer risk factors such as age, BMI, 
age at menarche and menopause, and reproductive 
  history were investigated in pre- and postmenopausal 
women separately. Subjects were divided according 
to age into five-year groups (,45 years, 45–49 years, 
50–54 years, 55–59 years, and $60 years);   according 
to BMI into four groups (,20 kg/m2, 20–,25 kg/m2, 
25–,30 kg/m2, and $30 kg/m2); according to age 
at menarche into four groups (,12 years, 12 years, 
13 years, and $14 years); according to number of 
live deliveries; and, in the case of parous women, 
according  to  age  at  first  live  delivery  into  three 
groups (,25 years, 25–29 years, and $30 years); 
according to total duration of breastfeeding (ie, the 
sum of the durations for which each child was breast-
fed) into five groups (never breastfed, 0–6 months, 
7–12 months, 13–24 months, and $25 months); and, 
finally, according to age at onset of menopause into 
four groups (,49 years, 49–50 years, 51–52 years, 
and $53 years).
A nonparametric test was conducted to ascertain 
the relationship between MGV and family history as 
well as that between MGV and menopausal status. 
Rank-sum correlation coefficients, ρ, were calculated 
to evaluate the correlation between MGV and breast 
cancer risk factors.
Case control study
For breast cancer patients, height and body weight 
were measured before breast cancer surgery, and the 
same  questionnaire  given  to  control  subjects  was 
administered. Preoperative chest CT data gathered for 
therapeutic planning were used. CT was performed 
Figure 1. estimation of mammary gland volume (MgV). 
note: The breast is manually identified on a binary CT image (outlined in black). Within the breast, areas with high CT values are considered to represent 
mammary gland tissue.
Mammary gland volume and breast cancer risk
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with a tube voltage of 120 kV; current was set auto-
matically. Images were collected and analyzed using 
the same protocols that were used for control subjects. 
MGV was measured on the unaffected side in breast 
cancer patients, and on the same side in each patient’s 
age-matched cases. The data from each patient’s two 
age-matched cases were used as control data.
In both breast cancer patients and controls, MGV, 
BMI, and other risk factors were examined through 
univariate analysis in premenopausal and postmeno-
pausal women separately. A nonparametric test was 
used  to  assess  statistical  significance.  Conditional 
logistic regression analysis was performed to exam-
ine the relationship between MGV and breast cancer. 
The subjects were divided into quartiles according to 
MGV, and the odds ratio for the subgroup with the 
lowest MGV to the other subgroups was determined 
(p for trend). In this analysis, factors used as risk fac-
tors in this report (BMI, age at menarche, number of 
deliveries, age at first delivery, breastfeeding dura-
tion, family history, and age at menopause in post-
menopausal women) were used as adjusted factors.
Statistical  analyses  were  conducted  using  SPSS 
software (SPSS Japan Inc., Tokyo, Japan), with the 
level of significance set at P , 0.05 (two-sided).
Results
Measurements and analysis  
of data from control subjects
The distribution of breast cancer risk factors in the 
427 healthy women is presented in Table 1. The sum 
correlation coefficient of concordance between left 
and right MGV as measured through CT was 0.91. 
The median MGV was 45.9 cm3 (interquartile range: 
22.2–78.2  cm3).  MGV  was  significantly  smaller 
in  postmenopausal  women  than  in  premenopausal 
women. The median MGV was 60.6 cm3 (interquartile 
range: 5.4–90.6 cm3) for women with a family history 
of breast cancer and 42.6 cm3 (19.5–71.6) for women 
without.  MGV  was  statistically  significantly  larger 
for women with a family history of breast cancer than 
for women without.
The relationships between MGV and breast cancer 
risk factors in the pre- and postmenopausal groups 
are listed in Table 2. For both pre- and postmeno-
pausal women, MGV was significantly smaller when 
table 1. Distribution of breast cancer risk factors and MgV 
(healthy women).
Factors number of  
subjects  
n = 427
Median  
(range)
Age (years) 427 50 (34–62)
BMI (kg/m²) 427 22.9  
(15.2–40.2)
Age at menarche  
(years)
427 12 (10–15)
number of deliveries  
(live births)
367 
(85.9%)
2 (1–3)
Age at first delivery  
(years) 
367 
(85.9%)
28 (21–37)
Duration of breastfeeding  
(months)
341 
(80.0%)
7 (0–60)
Positive family  
historya
48  
(11.2%)
Age at menopause  
(years)
163 
(38.2%)
50 (41–56)
note: aFamily history of breast cancer among first- and second-degree 
relatives.
the number of live births was high or the duration of 
breastfeeding was long. For postmenopausal women, 
MGV was significantly smaller when age at menarche 
was later or current age was older. For both pre- and 
postmenopausal  women,  no  significant  correlation 
was observed between BMI and MGV.
Case control study
The MGV and other breast cancer risk factor data for 
the 97 breast cancer patients and 194 healthy women 
are summarized in Table 3. Median MGVs for premeno-
pausal  and  postmenopausal  women  were  108.0  and 
53.0 cm3, respectively. Regardless of menopausal status, 
MGV was significantly higher in breast   cancer patients 
than in healthy women. Breast cancer patients, both pre-
menopausal and postmenopausal, had significantly low 
numbers of deliveries and significantly high BMIs and 
rates of family history of breast cancer. Postmenopausal 
breast  cancer  patients  reported  significantly  younger 
ages at menarche than their age-matched controls.
The results of our conditional logistic regression 
analysis for the relationship between MGV and breast 
cancer are presented in Table 4. Compared to the sub-
group with the smallest MGV, the highest odds ratio 
was observed in the subgroup with the largest MGV 
for both premenopausal and postmenopausal women. 
The highest odds ratio for premenopausal women was 
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Factors premenopausal postmenopausal
number of subjects Mammary gland 
volume (cm3) 
Median (IQR)
number of subjects Mammary gland 
volume (cm3)
Median (IQR)
Overall 264 57.9 (28.1–88.2) 163 33.6** (13.9–51.7)
Age (years) 264 163
  ,45 86 60.7 (28.1–91.3) 0
  45–49 102 55.9 (23.8–85.0) 3 33.6 (13.2–50.9)
  50–54 71 57.3 (33.5–87.1) 26 35.9 (9.9–54.1)
  55–59 5 93.5 (84.7–115.6) 107 37.2 (16.3–63.0)
  $60 0 27 19.1 (9.0–27.0)
  ρ 0.01 -0.16*
BMI 264 163
  ,20.0 37 57.8 (27.6–87.5) 3 41.3 (3.8–96.2)
  20.0 to ,25.0 149 57.3 (28.7–88.9) 98 30.2 (13.2–46.6)
  25.0 to ,30.0 74 58.5 (28.2–84.0) 48 40.2 (16.3–72.0)
  $30.0 4 71.6 (60.8–72.3) 14 38.9 (27.6–50.9)
   ρ -0.02 0.14
Age at menarche (years)  264 163
  ,12 72 49.8 (31.1–87.1) 34 45.7 (33.6–51.7)
  12  87 59.5 (30.7–79.1) 27 37.9 (14.2–45.2)
  13  45 63.6 (19.5–114.2) 54 22.2 (13.8–46.6)
   $14 60 57.8 (23.8–90.0) 48 30.4 (8.9–66.9)
   ρ -0.01 -0.18*
number of deliveries 
(live births)
264 163
   0 45 72.3 (58.2–99.0) 15 48.3 (33.6–100.3)
   1 39 74.9 (26.6–135.0) 27 30.4 (13.9–60.4)
   2 102 53.5 (23.5–81.0) 77 34.5 (14.2–51.7)
   3 78 47.3 (27.6–78.1) 44 25.2 (5.8–45.2)
   ρ -0.25** -0.19**
Age at first delivery (years) 219 148
  ,25 24 54.3 (27.6–74.7) 22 35.9 (14.2–44.6)
  25–29 119 49.4 (26.3–84.4) 109 27.2 (10.6–47.0)
 $ 30 76 58.5 (25.5–110.4) 17 51.7 (30.4–75.0)
 ρ 0.05 0.16
Breastfeeding duration 
(months)
264 163
  never breastfed 54 74.8 (59.1–99.0) 32 44.6 (19.1–80.6)
  0–6 96 69.0 (39.9–111.6) 73 34.5 (13.9–51.7)
  7–12 36 55.9 (24.6–96.4) 21 34.6 (13.8–53.7)
  13–24 49 29.8 (17.0–51.7) 15 23.8 (9.7–75.0)
 $ 25 29 29.9 (22.3–54.2) 22 22.2 (6.7–40.2)
 ρ -0.42** -0.16*
Age at menopause (years) 163
 , 49 33 33.6 (14.2–42.4)
  49–50 55 29.4 (13.9–51.6)
  51–52 40 30.4 (13.2–56.1)
 $ 53 35 40.3 (21.1–75.0)
 ρ       0.15
nonparametric test: *P , 0.05; **P , 0.01.
ρ = rank-sum correlation coefficient. 
Abbreviation: IQR, interquartile range.
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cases  
Median (range)
controls  
Median (range)
premenopausal Factors n = 34 n = 68
Mammary gland volume (cm3) (IQR) 108.0 (67.0–162.1)** 68.7 (40.6–110.9)
Age (years) 49 (34–54) 49 (34–56)
BMI 22.7 (16.0–39.8)** 19.6 (15.2–38.0)
Age at menarche (years) 12 (11–13) 12 (10–15)
number of deliveries (live births)  1 (0–2)** 2 (0–3)
Age at first delivery (years)  27 (23–36) 28 (22–36)
Breastfeeding duration (months)  2 (0–12) 1 (0–60)
Positive family history (%)a§ 14.7** 1.5
postmenopausal Factors n = 63 n = 126
Mammary gland volume (cm3) (IQR) 53.0 (30.4–108.0)** 34.2 (13.9–53.8)
Age (years) 58 (55–64) 59 (55–52)
BMI 24.6 (16.6–40.7)** 23.0 (19.3–35.6)
Age at menarche (years) 12 (10–14)** 13 (10–15)
number of deliveries (live births)  2 (0–3)** 2 (0–3)
Age at first delivery (years)  25 (23–37) 26 (23–33)
Breastfeeding duration (months)  3 (0–24) 6 (0–40)
Positive family history (%)a§ 9.5* 2.4
Age at menopause (years)  50 (42–54) 50 (45–56)
nonparametric test: *P , 0.05; **P , 0.01; §, chi-square test.
note: aFamily history of breast cancer among first- and second-degree relatives.
Abbreviation: IQR, interquartile range.
table 4. Odds ratio of each subgroup in relation to the subgroup with the lowest MgV (case control study).
Mammary gland 
volume (cm3)
cases controls Adjusted odds ratio 
(95% confidence interval)
P for trend
premenopausal n = 34 n = 68
,40.6 3 17 1
40.6–68.7 8 17 2.4 (0.5–10.7)
68.7–110.9 9 17 3.0 (0.7–13.1)
.110.9 14 17 4.9 (1.2–20.4)** 0.030
postmenopausal n = 63 n = 126
,13.9 8 31 1
13.9–34.2 10 32 1.1 (0.4–3.2)
34.2–53.8 17 32 1.8 (0.7–5.0)
.53.8 28 31 3.6 (1.4–9.1)** 0.007
Conditional logistic regression analysis: **P , 0.05.
notes: Postmenopausal adjusted factors: BMI, age at menarche, number of deliveries, age at first delivery, duration of breastfeeding, family history; 
Postmenopausal adjusted factors: BMI, age at menarche, number of deliveries, age at first delivery, duration of breastfeeding, family history, age at 
menopause.
4.9 (95% confidence interval: 1.2–20.4) for women 
with MGVs greater than 110.9; that for postmeno-
pausal  women  was  3.6  (95%  confidence  interval: 
1.4–9.1) for women with MGVs greater than 53.8. 
Regardless  of  menopausal  status,  the  greater  the 
MGV, the higher the odds ratio (P for trend among 
premenopausal  women  =  0.030,  and  P  for  trend 
among   postmenopausal women = 0.007).
Discussion
Breast cancer has been theoretically assumed to occur 
more  often  in  individuals  with  a  greater  volume  of 
mammary gland tissue in the breast. A previous study 
reported that involution in breast was associated with 
breast cancer reduction.11 MGV reflects the amount of 
fibroglandular tissue in the breast. The risk of suffering 
a malignant transformation should thus be in proportion 
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the relationship between exact gland volume and breast 
cancer risk, though our MGV measurement included 
not only mammary gland tissue but also fibrous and 
vascular components. Among premenopausal and post-
menopausal women alike, breast cancer patients exhib-
ited  statistically  significant  differences  from  healthy 
women in terms of MGV, BMI, number of deliveries, 
and incidence of positive family history of breast can-
cer. Regardless of menopausal status, the odds ratio 
increased with increasing MGV. We thus confirmed that 
high MGV, as measured using our technique for exact 
volume estimation, is a risk factor for breast cancer.
We  estimated  the  exact  gland  volume  as  MGV 
using chest CT data. The volume of mammary gland 
tissue can be evaluated more precisely by chest CT 
than  by  mammogram  because  recent  advances  in 
CT technology have enabled three-dimensional esti-
mates. Nevertheless, no previous report has studied 
gland volume using measurements obtained through 
CT. This may be due to a desire to avoid exposing 
study subjects to unnecessary radiation. The present 
study, however, did not require participants to receive 
any unnecessary radiation exposure because we used 
CT data that had been obtained previously for another 
purpose. The rate of concordance between left and 
right MGV was very high, indicating the reliability of 
MGV measurements obtained through CT.
Many  studies  have  investigated  the  relation-
ship between MD and breast cancer, which remains 
unclear. The most important factors influencing the 
determination  of  an  individual’s  breast  cancer  risk 
based on MD are body weight and BMI. Many previ-
ous studies have found that BMI is inversely related to 
MD. Boyd et al found an inverse correlation between 
absolute density and BMI,5 that is, between absolute 
density and absolute nondensity areas, indicating that, 
when breast cancer risk is estimated on the basis of 
MD, higher BMI is associated with lower estimates. 
This is in sharp contrast to the fact that higher BMI is 
associated with higher breast cancer risk; particularly 
among  postmenopausal  women,  the  importance  of 
obesity as a risk factor is well established.12 The pres-
ent study found no correlation between BMI and MGV 
in healthy women. High BMI and larger MGV were 
scored in breast cancer patients. Our results   suggest 
that  MGV  and  fat  volume  independently  influence 
breast cancer risk, which is not seen in MD with fat 
density (body weight and BMI). These results make 
good sense in understanding that MD is an interme-
diate factor in breast cancer risk. For these reasons, 
we support Boyd et al’s recommendation that breast 
cancer risk be assessed on the basis of MGV and fat 
volume as separate measurements rather than on MD.
We investigated the relationship between MGV and 
breast cancer risk factors in control subjects. In both 
premenopausal  and  postmenopausal  women,  MGV 
was correlated with number of deliveries, breastfeed-
ing duration, and family history of breast cancer. In 
postmenopausal women, it was correlated with age 
and with age at menarche. Our results were similar in 
many ways to the results of previous studies assess-
ing breast cancer risk based on MD or mammographic 
dense  tissue.13–15  The  relationship  between  family 
history of breast cancer and high MD has been clari-
fied many studies; it is known that family history and 
genetic factors can influence MD.16,17 In the present 
study, women with a family history of breast cancer 
had significantly greater MGVs than those without; 
this suggests that MGV is correlated to a family his-
tory of breast cancer. In fact, the rate of positive family 
history was significantly higher in patients with breast 
cancer  than  in  healthy  women  in  our  case  control 
study. Thus, the genetic factors that determine gland 
volume might also determine breast cancer risk.
While  there  have  been  several  reports  that  have 
estimated fibroglandular tissue volume in breast MRI 
images,18,19 we could not find any previous epidemio-
logical reports that investigated the relationship between 
breast  cancer  risk  and  precise  three-  dimensional 
  “mammary  (fibroglandular  tissue)  volume”.  There 
has  only  been  one  epidemiological  report  based  on 
volumetric  breast  density  through  mammography.20 
Nevertheless,  volumetric  breast  density  is  not  equal 
to MGV because of the difference in the state of the 
breast—whether or not it is compressed. Our method is 
excellent in that measurements are conducted with the 
breast in its natural state, not compressed as in mam-
mography. In addition, it is frequently difficult to exam-
ine the entire breast using conventional mammography 
due to partial deficits in dense tissue,   particularly among 
  Japanese women who tend to have small breasts. With 
CT, all areas of the breast can be examined and MGV 
can be measured. These breast imaging deficits have not 
previously been discussed in any published   European 
or American studies assessing breast cancer risk.
Mammary gland volume and breast cancer risk
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Limitations of the present study include the small 
number of breast cancer patients and the fact that our 
measurements of the volume of nonfat tissue included 
fibrous and vascular components that are less likely 
to be related to breast cancer than glandular tissue. 
Nevertheless, our results constitute the first reliable 
data  on  the  relationship  between  mammary  gland 
  volume and breast cancer obtained through exact vol-
ume analysis. Because it exposes patients to a high 
dose of radiation, we do not recommend that chest 
CT be routinely used to assess breast cancer risk.
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